Array ( [1614670773] => Array ( [wp_privacy_delete_old_export_files] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1614671281] => Array ( [wpm_update_stats] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1614672792] => Array ( [wordfence_hourly_cron] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1614674971] => Array ( [wp_scheduled_auto_draft_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614680111] => Array ( [delete_expired_transients] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614680152] => Array ( [wpseo-reindex-links] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614680814] => Array ( [wordfence_daily_cron] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614691926] => Array ( [wp_update_themes] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) [wp_update_plugins] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1614692674] => Array ( [wp_scheduled_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614695353] => Array ( [wp_version_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1614698273] => Array ( [wp_session_garbage_collection] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1614701224] => Array ( [akismet_scheduled_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614704211] => Array ( [yoast_tracking] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614721261] => Array ( [wpseo_permalink_structure_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) [wpseo_home_url_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614721274] => Array ( [wpseo-reindex] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614752685] => Array ( [recovery_mode_clean_expired_keys] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614752690] => Array ( [wp_site_health_scheduled_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => weekly [args] => Array ( ) [interval] => 604800 ) ) ) [1614755312] => Array ( [ai1wm_storage_cleanup] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1614865801] => Array ( [wordfence_start_scheduled_scan] => Array ( [711b553db1ed5114c2e3b577ebcc832b] => Array ( [schedule] => [args] => Array ( [0] => 1614865801 ) ) ) ) [1615125001] => Array ( [wordfence_start_scheduled_scan] => Array ( [a9dac4ceaad9699bac1bb8e7da9993e7] => Array ( [schedule] => [args] => Array ( [0] => 1615125001 ) ) ) ) )
Etiquetas: 15 abril 2011, 15/04/2011, AEMPS, Agencia española de medicamentos y productos sanitarios, Agencia Europea de Medicamentos, Bisfosfonatos, Centro Autonómico de Farmacovigilancia, CHMP, Comité de Medicamentos de Uso Humano, EMA, Fractura atípica femoral, Fracturas atípicas de femur, Fracturas atípicas femorales, Madrid, medicamentos, Normativa interna, Nota informativa, Profesionales sanitarios, Riesgo, salud, Sanidad, seguridad, Situación clínica del paciente, Tratamiento, Uso humano.
Etiquetas: 15 abril 2011, 15/04/2011, AEMPS, Agencia española de medicamentos y productos sanitarios, Agencia Europea de Medicamentos, Agencias nacionales europeas, Alendronato, Biosfatos, CHMP, Clodronato, Comité de Medicamentos de Uso Humano, EMA, Etidronato, Fracturas atípicas de femur, Ibandronato, Medicamentos de uso humano, MUH, Pacientes en tratamiento con bisfosfonatos, Pamidronato, Profesionales sanitarios, Riesgos de fracturas atípicas de femur, Risedronato, salud, Sanidad, seguridad, Tiludronato, Tratamiento con bisfosfonatos, Tratamiento con el bisfosfonato, Tratamiento de la osteoporosis con bisfosfonatos, Zolendronato.